The stel­lar an­ti­body shop at Re­gen­eron wins a ‘break­through’ tag for its next big PhI­II drug

Re­gen­eron $REGN has one of the best track records in the busi­ness when it comes to build­ing amaz­ing­ly ef­fec­tive an­ti­bod­ies. It did it with Dupix­ent for eczema and Pralu­ent for cho­les­terol. And now one of its Phase II stars just earned a break­through tag from the FDA, which puts it on the in­side track at the agency as it goes in­to piv­otal stud­ies for slash­ing triglyc­eride.

The drug is evinacum­ab. The tar­get is once again ex­tra­or­di­nar­i­ly high lev­els of LDL cho­les­terol. But the tar­get is dif­fer­ent. This an­ti­body tack­les an­giopoi­etin-like pro­tein 3, or ANGPTL3. ANGPTL3 in­hibits lipopro­tein li­pase and en­dothe­lial li­pase, play­ing a key role in lipopro­tein me­tab­o­lism.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.